INT148341

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.65
First Reported 2005
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 9
Total Number 9
Disease Relevance 4.19
Pain Relevance 0.68

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (MAS1) plasma membrane (MAS1) signal transducer activity (MAS1)
Anatomy Link Frequency
capsule 2
MIs 1
superior 1
DRG 1
T cells 1
MAS1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 23 99.90 Very High Very High Very High
Infliximab 20 99.48 Very High Very High Very High
Onset of action 4 96.24 Very High Very High Very High
agonist 9 75.00 Quite High
Etanercept 15 73.12 Quite High
headache 16 69.80 Quite High
Bioavailability 63 66.76 Quite High
cytokine 27 65.84 Quite High
Sciatic nerve 1 55.76 Quite High
Central nervous system 3 46.04 Quite Low
Disease Link Frequency Relevance Heat
Polyostotic Fibrous Dysplasia 59 100.00 Very High Very High Very High
INFLAMMATION 23 99.90 Very High Very High Very High
Apoptosis 36 99.84 Very High Very High Very High
Nociception 1 99.60 Very High Very High Very High
Sleep Disorders 57 99.40 Very High Very High Very High
Disease 68 98.96 Very High Very High Very High
Attention Deficit Hyperactivity Disorder 443 97.56 Very High Very High Very High
Cancer 20 93.80 High High
Fibrous Dysplasia Of Bone 84 93.00 High High
Congenital Anomalies 3 92.76 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
A recently described family of "orphan" receptors, called Mas-related G-protein-coupled receptors (Mrg), is preferentially expressed in small nociceptive neurons of the rodent and human dorsal root ganglia (DRG).
Gene_expression (expressed) of Mas in DRG associated with nociception
1) Confidence 0.65 Published 2008 Journal Neuroscience Section Abstract Doc Link 18065157 Disease Relevance 0.10 Pain Relevance 0.07
These data suggest that urinary levels of MAsIII, the most toxic species among identified metabolites of iAs, may serve as an indicator to identify individuals with increased susceptibility to toxic and cancer-promoting effects of arseniasis.



Gene_expression (levels) of MAsIII associated with cancer
2) Confidence 0.56 Published 2005 Journal Environ Health Perspect Section Abstract Doc Link PMC1253747 Disease Relevance 0.20 Pain Relevance 0
This study found that both MAS XR and LDX produced similar improvements, both of which were superior at all doses as compared to placebo.
Gene_expression (produced) of MAS XR in superior
3) Confidence 0.23 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2877609 Disease Relevance 0.31 Pain Relevance 0
Malignancies in MAS
Gene_expression (Malignancies) of MAS associated with polyostotic fibrous dysplasia
4) Confidence 0.22 Published 2008 Journal Orphanet J Rare Dis Section Body Doc Link PMC2459161 Disease Relevance 1.45 Pain Relevance 0
With the delayed-release component, the capsule, taken once/day, MAS XR produced similar pharmacokinetic and pharmacodynamic effects to immediate-release MAS taken twice/day.
Gene_expression (produced) of MAS XR in capsule
5) Confidence 0.05 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697545 Disease Relevance 0.28 Pain Relevance 0.11
With the delayed-release component, the capsule, taken once/day, MAS XR produced similar pharmacokinetic and pharmacodynamic effects to immediate-release MAS taken twice/day.
Gene_expression (produced) of immediate-release MAS in capsule
6) Confidence 0.04 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697545 Disease Relevance 0.29 Pain Relevance 0.12
Most studies have not shown a difference between CPAP and MAS therapy in subjective sleepiness (Tan et al 2002; Barnes et al 2004) although CPAP is more effective in reducing AHI (Ferguson et al 1997; Barnes et al 2004).
Gene_expression (therapy) of MAS associated with sleep disorders
7) Confidence 0.04 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671821 Disease Relevance 0.71 Pain Relevance 0
During latency, TNF levels (Figure 1E) are on the order of 0.12 pg/mL (limited inflammation) as levels of MIs and MAs (activated microphages) are relatively low (and these are major TNF producers).
Gene_expression (levels) of MAs in MIs associated with inflammation
8) Confidence 0.02 Published 2007 Journal PLoS Computational Biology Section Body Doc Link PMC2041971 Disease Relevance 0.74 Pain Relevance 0.11
Further, due to the nature of its interaction with tmTNF, infliximab induces apoptosis in TNF-producing cells (including MIs and MAs, CD4+ and CD8+ T cells) via a caspase-dependent pathway [52].
Gene_expression (producing) of MAs in T cells associated with infliximab and apoptosis
9) Confidence 0.01 Published 2007 Journal PLoS Computational Biology Section Body Doc Link PMC2041971 Disease Relevance 0.10 Pain Relevance 0.27

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox